POLIVY®
polatuzumab vedotin

Mechanism of action

Polatuzumab vedotin is a member of an innovative drug class called antibody drug conjugates or ADCs. These targeted therapies have been found to be effective in various treatment settings. Polatuzumab vedotin consists of a monoclonal antibody conjugated with the potent cytotoxic drug MMAE via a protease cleavable linker.

This linker provides stability to the drug until it reaches its site of action where MMAE is released.

The target of the monoclonal antibody is CD79b, a component of the B-cell receptor. The B-cell receptor is constitutively expressed on the surface of all B cells, including malignant B cells.

After binding to CD79b polatuzumab vedotin and the B cell receptor are internalised. Inside the cell, the linker of polatuzumab vedotin is degraded. MMAE is released into the cytoplasm, where it interrupts the polymerisation of microtubules.

This inhibits cell division and may eventually lead to apoptosis. MMAE is not degraded in the cell, and some evidence suggests that it could spread to neighbouring cells upon apoptosis, possibly disrupting the microenvironment of the tumor.

POLIVY®
polatuzumab vedotin

References:
1. WHO. World Cancer Report 2014. Accessed July 5, 2018.
2. Rovira J, Valera A, Colomo L, et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015;94(5):803-812.
3. Mey U, Hitz F, Lohri A, et al. Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Med Wkly. 2012;142:w13511.
4. Larouche J-F, Berger F, Chassagne-Clément C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: Clinical characteristics and outcome. J Clin Oncol. 2010;28(12):2094-2100.
5. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22-32.
6. Gisselbrecht C, van den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182(5):633-643.
7. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:116-25.
8. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.
9. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-1545.
10. van den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: An analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216-221.
11. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARD Study. J Clin Oncol. 2017;35(5):544-551.
12. Vaughan J. Polatuzumab Vedotin Scientific Platform: Relapsed/refractory Diffuse Large B-cell Lymphoma;October 2017(NP/PIPE/1710/0023).
13. Sehn LH, Herrera AF, Matasar MJ, et al. Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study. Accessed April 4, 2018.
14. Lu D, Gibiansky L, Agarwal P, et al. Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling. CPT Pharmacometrics Syst Pharmacol. 2016;5(12):665-673.
15. Drake PM, Rabuka D. Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends. BioDrugs. 2017;31(6):521-531.
16. Lu J, Jiang F, Lu A, Zhang G. Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int J Mol Sci. 2016;17(4):561.
17. Schweighoffer E, Tybulewicz VL. Signalling for B cell survival. Curr Opin Cell Biol. 2017;51:8-14.
18. Gururajan M, Jennings CD, Bondada S. Cutting edge: Constitutive B cell receptor signaling is critical for basal growth of B lymphoma. The Journal of Immunology. 2006;176(10):5715-5719.
19. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013;5(1):13-21.
20. Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC Linker Chemistry. Pharm Res. 2015;32(11):3526-3540.
21. Caculitan NG, Dela Cruz Chuh J, Ma Y, et al. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates. Cancer Res. 2017;77 (24):7027-7037.
22. Waight AB, Bargsten K, Doronina S, Steinmetz MO, Sussman D, Prota AE. Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics. PLoS ONE. 2016;11(8):0160890.
23. Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates--a new wave of cancer drugs. Bioorg Med Chem Lett. 2014;24(23):5357-5363.
24. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3): 888-897.25.
25. Sehn LH, Herrera AF, Matasa M, et al. Polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/ refractory (R/R) diffuse large B-cell lymphoma (DLBCL): updated results of a phase (Ph) Ib/Il study. Poster presented at: 60th ASH; December 1-4, 2018; San Diego, CA.
26. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Accessed July 15, 2019.
27. Sehn LH, Flowers C, McMillan A, et al. Estimation of long-term survival with polatuzumab vedotin plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Poster presented at: 15th ICML; 18-22 June 2019; Lugano, Switzerland.
28. NIH. A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma. https://clinicaltrials.gov/ct2/show/NCT03274492. Accessed July 5, 2018.
29. NIH. A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma. https://clinicaltrials.gov/ct2/show/NCT02257567. Accessed July 5, 2018.
30. NIH. A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma. https://clinicaltrials.gov/ct2/show/NCT01992653. Accessed July 5, 2018.
31. European Medicines Agency. Public summary of opinion on orphan designation Polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2018/05/WC500249080.pdf. Accessed June 11, 2018.
32. U.S. Food and Drug Administration. POLIVY (IV): Full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf. Accessed July 15, 2019.
33. F. Hoffmann-La Roche Ltd. Phase II data showed Roche's investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma. https://www.roche.com/dam/jcr:33daefa2-e6fd-4054-8494-af3e50a76f9f/en/171210_MR_Polatuzumab_en.pdf. Updated December 10, 2017. Accessed June 11, 2018.

This medicinal product is subject to additional monitoring in EU countries.
This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

POLIVY®
polatuzumab vedotin